Cargando…
Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
Traumatic brain injury (TBI) occurs in a large percentage of surgical trauma patients and is one of the leading causes of death amongst young teens and adults. Furthermore, individuals with TBIs often require mechanical ventilation and admission to the intensive care unit. As a result of their TBIs,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534192/ https://www.ncbi.nlm.nih.gov/pubmed/36258708 http://dx.doi.org/10.14740/jmc3983 |
_version_ | 1784802487733059584 |
---|---|
author | Malkoc, Aldin Stading, Ashley Wong, Stephanie Weaver, Tara Ghisletta, Leslie |
author_facet | Malkoc, Aldin Stading, Ashley Wong, Stephanie Weaver, Tara Ghisletta, Leslie |
author_sort | Malkoc, Aldin |
collection | PubMed |
description | Traumatic brain injury (TBI) occurs in a large percentage of surgical trauma patients and is one of the leading causes of death amongst young teens and adults. Furthermore, individuals with TBIs often require mechanical ventilation and admission to the intensive care unit. As a result of their TBIs, these patients can develop central alveolar hypoventilation (CAH) secondary to disruptions in neuromodulatory respiratory brainstem control and neural signal initiation and integration. Prior studies have primarily focused their attention on treatment of congenital disorders of CAH, and limited research is available on intubated trauma patients who have signs of ventilator dyssynchrony. Current case reports and animal studies have suggested that noradrenergic and specific serotonergic medications are able to target specific neurologic pathways in the respiratory circuit and induce ventilator synchrony. This case series describes the clinical course of TBI patients treated for ventilator dyssynchrony secondary to CAH with a daily scheduled 5-hydroxytryptamine-3 (5-HT3) receptor antagonist. All patients were ultimately extubated and discharged from the hospital. |
format | Online Article Text |
id | pubmed-9534192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95341922022-10-17 Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist Malkoc, Aldin Stading, Ashley Wong, Stephanie Weaver, Tara Ghisletta, Leslie J Med Cases Case Report Traumatic brain injury (TBI) occurs in a large percentage of surgical trauma patients and is one of the leading causes of death amongst young teens and adults. Furthermore, individuals with TBIs often require mechanical ventilation and admission to the intensive care unit. As a result of their TBIs, these patients can develop central alveolar hypoventilation (CAH) secondary to disruptions in neuromodulatory respiratory brainstem control and neural signal initiation and integration. Prior studies have primarily focused their attention on treatment of congenital disorders of CAH, and limited research is available on intubated trauma patients who have signs of ventilator dyssynchrony. Current case reports and animal studies have suggested that noradrenergic and specific serotonergic medications are able to target specific neurologic pathways in the respiratory circuit and induce ventilator synchrony. This case series describes the clinical course of TBI patients treated for ventilator dyssynchrony secondary to CAH with a daily scheduled 5-hydroxytryptamine-3 (5-HT3) receptor antagonist. All patients were ultimately extubated and discharged from the hospital. Elmer Press 2022-09 2022-09-28 /pmc/articles/PMC9534192/ /pubmed/36258708 http://dx.doi.org/10.14740/jmc3983 Text en Copyright 2022, Malkoc et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Malkoc, Aldin Stading, Ashley Wong, Stephanie Weaver, Tara Ghisletta, Leslie Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist |
title | Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist |
title_full | Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist |
title_fullStr | Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist |
title_full_unstemmed | Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist |
title_short | Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist |
title_sort | novel treatment of ventilator dyssynchrony from central alveolar hypoventilation syndrome utilizing scheduled 5-hydroxytryptamine-3 receptor antagonist |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534192/ https://www.ncbi.nlm.nih.gov/pubmed/36258708 http://dx.doi.org/10.14740/jmc3983 |
work_keys_str_mv | AT malkocaldin noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist AT stadingashley noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist AT wongstephanie noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist AT weavertara noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist AT ghislettaleslie noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist |